| 書名 | 作者 | 出版年 | 查看 | 回報錯誤連結 |
|---|
| Resistance to tyrosine kinase inhibitors |
Daniele Focosi. |
2016 |
查看
|
回報問題連結 |
| Cancer drug discovery:science and history / |
Kyu-Won Kim ... [et al.]. |
2016 |
查看
|
回報問題連結 |
| Dose-finding designs for early-phase cancer clinical trials :a brief guidebook to theory and practice / |
Takashi Daimon, Akihiro Hirakawa, Shigeyuki Matsui. |
|
查看
|
回報問題連結 |
| Anti-cancer N-heterocyclic carbene complexes of gold(III), gold(I) and platinum(II) :thiol "switch-on" fluorescent probes, thioredoxin reductase inhibitors and endoplasmic reticulum targeting agents / |
Taotao Zou. |
|
查看
|
回報問題連結 |
| Razoxane and dexrazoxane - two multifunctional agents:experimental and clinical results / |
Kurt Hellmann, Walter Rhomberg. |
2010 |
查看
|
回報問題連結 |
| Next generation antibody drug conjugates (ADCs) and immunotoxins |
Ulf Grawunder, Stefan Barth. |
2017 |
查看
|
回報問題連結 |
| Biotechnology and production of anti-cancer compounds |
Sonia Malik. |
2017 |
查看
|
回報問題連結 |
| Modern dose-finding designs for cancer phase I trials:drug combinations and molecularly targeted agents / |
Akihiro Hirakawa ... [et al.]. |
2018 |
查看
|
回報問題連結 |
| New approaches to natural anticancer drugs / |
Soodabeh Saeidnia. |
|
查看
|
回報問題連結 |
| Principles of anticancer drug development |
Elizabeth Garrett-Mayer ... [et al.]. |
2011 |
查看
|
回報問題連結 |
| Drugs for HER-2-positive breast cancer |
Maria Sibilia ... [et al.]. |
2011 |
查看
|
回報問題連結 |
| Therapeutic kinase inhibitors |
Ingo K. Mellinghoff, Charles L. Sawyers ; responsible series editor: Peter K. Vogt. |
2012 |
查看
|
回報問題連結 |
| Phase I oncology drug development / |
Timothy A. Yap, Jordi Rodon, David S. Hong. |
|
查看
|
回報問題連結 |
| Advances and prospects of 3-D metal-based anticancer drug candidates / |
Farukh Arjmand, Sartaj Tabassum, Huzaifa Yasir Khan. |
|
查看
|
回報問題連結 |
|
|
